Skip to content
Menu

Harmony Biosciences Holdings, Inc. HRMY

Full chart Compare
Set alert

Price alert · HRMY

All alert types
33.76 USD -0.04 (-0.12%)

Regular-session close

33.76 0.00 0.00%

After hours · Nov 13, 4:00 PM ET

33.01 Day range 34.32
26.54 52-week range 42.86
YTD
-9.78%
1 year
-1.55%
Market cap
1.98B
Revenue (ttm)
989.36M
Profit margin
18.05%
EPS (ttm)
3.02
Shares out
58.72M
P/E ratio
11.18
Forward P/E
5.57
YTD return
-9.78%
1-year return
-1.55%
Volume
844.89K
Avg volume
1.00M
Open
33.80
Previous close
33.80
Day's range
33.01 – 34.32
52-week range
26.54 – 42.86
Beta
0.98
Analysts
Buy
Price target
48.08 (+42.4%)
Earnings date
Feb 23, 2027

5D +0.70 (+2.12%)

3333.5034MonTueWedThuFri33.72

Key statistics

Enterprise value
1.37B
PEG ratio
0.00
Price / sales
2.00
Price / book
1.85
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
12.30%
Free cash flow
191.78M
Total cash
771.14M
Total debt
154.91M
Return on equity
18.73%
Short % of float
15.12%
50-day average
38.81
200-day average
34.59

Fundamental scorecard

18 of 25 checks passed on HRMY’s reported financials

Value: 5/5ValueGrowth: 4/5GrowthProfitability: 4/5ProfitabilityFinancial health: 5/5HealthDividend: 0/5Dividend

18of 25 checks passed

  • Value 5 of 5
  • Growth 4 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
HRMY Revenue — quarterly 268.92M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
HRMY Net income — quarterly 48.20M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
HRMY EPS — quarterly 0.83
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

HRMY recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20261.09———
Nov 4, 2026Sep 30, 20261.090.81-0.28-25.69%
Aug 4, 2026Jun 30, 20260.9561.28+0.32+33.89%
May 7, 2026Mar 31, 20260.760.55-0.21-27.63%
Feb 24, 2026Dec 31, 20250.840.38-0.46-54.76%
Nov 4, 2025Sep 30, 20250.920.87-0.05-5.43%

Upgrades / downgrades

HRMY analyst upgrades and downgrades
DateFirmActionFromTo
Nov 12, 2026HC Wainwright & Co.reitBuyBuy
Oct 19, 2026NeedhamreitBuyBuy
Oct 13, 2026HC Wainwright & Co.reitBuyBuy
Oct 12, 2026NeedhamreitBuyBuy
Aug 26, 2026Wolfe Researchinit—Outperform
Aug 5, 2026Truist SecuritiesmainHoldHold

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on HRMY — it syncs with the Stock Master app.

Insider holders

HRMY insider holders
InsiderRelationLatest transactionDateShares held
BUDUR KUMAROfficerSaleSep 7, 202613,115
DAYNO JEFFREY MChief Executive OfficerConversion of Exercise of derivative securityJan 22, 20267,346
DIERKS JEFFREY GOfficerSaleMar 2, 20250
KAPADIA SANDIPChief Financial OfficerSaleJan 25, 202624,521
SERAFIN ANDREWOfficerConversion of Exercise of derivative securityJan 22, 20261,474
ZAESKE ADAM H.OfficerConversion of Exercise of derivative securityApr 6, 20264,327

Institution ownership

HRMY institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.09%7,101,965239.76MJun 29, 2026
FMR, LLC6.09%3,574,115120.66MJun 29, 2026
Vanguard Portfolio Management LLC4.91%2,880,48997.25MJun 29, 2026
Dimensional Fund Advisors LP4.51%2,649,97589.46MSep 29, 2026
American Century Companies Inc4.32%2,539,51285.73MJun 29, 2026
LSV Asset Management3.75%2,205,02274.44MSep 29, 2026

Fund ownership

HRMY fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.02%2,946,36599.47MSep 29, 2026
American Century ETF Trust-Avantis U.S. Small Cap Value ETF4.49%2,638,65189.08MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.65%1,556,60252.55MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.99%1,168,76939.46MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.92%1,127,55938.07MJun 29, 2026
Fidelity Commonwealth Trust II-Fidelity Enhanced Small Cap Core ETF1.22%715,32324.15MSep 29, 2026